Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tvardi Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
TVRD
Nasdaq
2836
tvarditherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tvardi Therapeutics, Inc.
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
- Oct 14th, 2026 6:00 am
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
- Sep 24th, 2026 6:00 am
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
- Aug 14th, 2026 5:00 am
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
- Aug 12th, 2026 6:00 am
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
- Jul 30th, 2026 5:30 am
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
- Jul 9th, 2026 8:52 am
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
- Jul 7th, 2026 5:00 am
Tvardi Therapeutics to Participate in Upcoming Investor Events
- May 21st, 2026 6:00 am
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
- May 8th, 2026 5:00 am
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
- Apr 2nd, 2026 6:00 am
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
- Mar 31st, 2026 2:01 pm
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
- Feb 12th, 2026 6:00 am
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate
- Feb 7th, 2026 6:48 am
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
- Jan 8th, 2026 6:00 am
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Nov 18th, 2025 7:55 am
Scroll